Hims & Hers shares fell for a third straight session after Truist reiterated a Hold rating and flagged new GLP-1 intake updates, including Klarna financing, shorter shipping intervals and microdosing options. The company also launched its biomarker-testing service, Hims Labs. A filing showed Chief Legal Officer Soleil Teubner Boughton sold 2,637 shares on November 10.